{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.5","value":"85.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"136"}],"units":"Participants"}],"description":"Vp/F is defined as the apparent volume of distribution for the tissue (peripheral) compartment.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with FGFR2 rearrangements or fusions (Cohort A), participants with all other FGF/FGFR alterations (Cohort B), participants with no FGF/FGFR alterations (Cohort C; United States only), and participants with an FGF/FGFR status for whom the local laboratory FGF/FGFR results could not be confirmed centrally (Other) self-administered oral pemigatinib at a starting dose of 13.5 mg QD on a 2-weeks-on therapy/1-week-off schedule in 21-day cycles. Pemigatinib was administered until documented disease progression or unacceptable toxicity.","id":"OG000","title":"All Cohorts"}],"paramType":"MEAN","populationDescription":"PK Population","reportingStatus":"POSTED","timeFrame":"Predose; 1-2 hours post-dose; 4-12 hours post-dose","title":"Vp/F of Pemigatinib","type":"SECONDARY","unitOfMeasure":"Liters"}